Related Experiment Video

Updated: Jun 6, 2026

Experimental Human Pneumococcal Carriage
07:47

Experimental Human Pneumococcal Carriage

Published on: February 15, 2013

Outcomes and costs associated with PHiD-CV, a new protein D conjugate pneumococcal vaccine, in four countries

Sandra E Talbird1, Thomas N Taylor, Stefanie Knoll

  • 1RTI Health Solutions, PO Box 12194, 3040 Cornwallis Road, Research Triangle Park, NC 27709, USA. stalbird@rti.org

Vaccine
|November 16, 2010
PubMed

Insights

Routine infant vaccination with the 10-valent pneumococcal nontypeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) prevented more disease and deaths than PCV-7. PHiD-CV also offered lower costs, assuming price parity.

Area of Science:

  • Public Health
  • Vaccinology
  • Health Economics

Background:

  • Pneumococcal conjugate vaccines (PCVs) are crucial for preventing invasive pneumococcal disease.
  • Evaluating new vaccine candidates like the 10-valent pneumococcal nontypeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) is essential for optimizing public health strategies.
  • Understanding the comparative impact of different valency PCVs on health outcomes and costs is vital for healthcare decision-making.

Purpose of the Study:

  • To estimate the population-level impact of routine infant vaccination with PHiD-CV compared to the 7-valent pneumococcal conjugate vaccine (PCV-7).
  • To assess differences in health outcomes (disease cases prevented, deaths prevented, life-years gained, quality-adjusted life-years gained) and costs in Canada, Germany, Mexico, and Norway.
  • To evaluate both short-term (10-year) and steady-state impacts of PHiD-CV versus PCV-7.

Main Methods:

  • A compartmental, static, steady-state population model was utilized.
  • The model incorporated direct and indirect vaccine effects, including herd immunity and serotype replacement.
  • Calculations included disease and death prevention, life-years gained, quality-adjusted life-years gained, and incremental costs, all in 2008 local currency.

Main Results:

  • PHiD-CV vaccination prevented more disease cases and deaths compared to PCV-7 across all analyzed countries.
  • Increased life-years and quality-adjusted life-years were estimated for PHiD-CV versus PCV-7 in both short-term and steady-state analyses.
  • Assuming price parity, PHiD-CV demonstrated lower costs compared to PCV-7 in both timeframes.

Conclusions:

  • Routine infant immunization with PHiD-CV offers superior health benefits over PCV-7.
  • PHiD-CV is projected to be more cost-effective than PCV-7, particularly under price parity.
  • The duration of vaccine efficacy is a key factor influencing the cost-effectiveness of PHiD-CV.

More Related Videos

Homogeneous Glycoconjugate Produced by Combined Unnatural Amino Acid Incorporation and Click-Chemistry for Vaccine Purposes13:53

Homogeneous Glycoconjugate Produced by Combined Unnatural Amino Acid Incorporation and Click-Chemistry for Vaccine Purposes

Published on: December 19, 2020

Opsono-Adherence Assay to Evaluate Functional Antibodies in Vaccine Development Against Bacillus anthracis and Other Encapsulated Pathogens13:47

Opsono-Adherence Assay to Evaluate Functional Antibodies in Vaccine Development Against Bacillus anthracis and Other Encapsulated Pathogens

Published on: May 19, 2020

Related Concept Videos

Conjugated Proteins02:50

Conjugated Proteins

Simple proteins and protein complexes contain only amino acids. In contrast, many other proteins, called conjugated proteins, covalently bond with non-protein moieties.
Nucleoproteins are protein complexes that contain nucleic acids, categorized as deoxyribonucleoproteins (DNPs) or ribonucleoproteins (RNPs) respectively. The nucleosome is a typical example of a DNP where nuclear DNA is associated with histone proteins. The major antigen for the Covid-19 virus SARS-CoV is an RNP that is critical...
Streptococcal Pharyngitis01:27

Streptococcal Pharyngitis

Streptococcal pharyngitis, commonly known as “strep throat,” is an acute infection of the oropharyngeal tissues caused by the Gram‑positive Group A Streptococcus (Streptococcus pyogenes). Transmission occurs primarily through respiratory droplets expelled during coughing, sneezing, or talking.Mechanisms of Host Entry and Immune EvasionUpon entering the host, S. pyogenes adheres to the mucosal epithelial cells of the pharynx via surface proteins, notably lipoteichoic acid and the antiphagocytic...
Vaccine Production01:23

Vaccine Production

Vaccine production involves a sequence of upstream and downstream processes to generate a safe and effective immunological product. It begins with cultivating microorganisms, such as viruses or bacteria, to obtain antigenic material. For viral vaccines, mammalian host cells are grown in bioreactors and subsequently infected with the target virus. The virus replicates within the host cells, which are lysed to release viral particles. This lysate is then clarified through filtration or...
Vaccinations01:51

Vaccinations

Overview
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches01:23

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...
Acute Pharyngitis01:30

Acute Pharyngitis

Introduction
Acute pharyngitis is the inflammation of the back of the throat (pharynx), commonly resulting in a sore throat. It is a frequently encountered condition that prompts individuals to seek medical advice.
Classification
Acute pharyngitis can be categorized based on its underlying cause: